文献速递脑血管病外科神经重症

双联抗血小板治疗与动脉瘤性蛛网膜下腔出血患者临床血管痉挛及迟发性脑缺血风险降低的相关性

Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia.
PubMed 文献 · J Neurosurg · 2017-11-03

单中心回顾性研究纳入161例动脉瘤性蛛网膜下腔出血患者,比较需双联抗血小板治疗(DAPT)的支架辅助弹簧圈栓塞或血流导向装置置入组(85例)与单纯弹簧圈栓塞未用DAPT组(76例)。DAPT组临床血管痉挛(OR 0.244,95%CI 0.097-0.615,p=0.003)和迟发性脑缺血(OR 0.056,95%CI 0.01-0.318,p=0.001)风险显著降低,两组外引流及脑室腹腔分流相关出血并发症发生率相似(4% vs 2%,p=0.9)。

要点

  • DAPT组临床血管痉挛风险显著低于对照组(OR 0.244,95%CI 0.097-0.615,p=0.003)。
  • DAPT组迟发性脑缺血风险显著低于对照组(OR 0.056,95%CI 0.01-0.318,p=0.001)。
  • 两组外引流及分流相关出血并发症发生率相似(4% vs 2%,p=0.9)。

核心结论

  • 在动脉瘤性蛛网膜下腔出血患者中,使用双联抗血小板治疗与临床血管痉挛和迟发性脑缺血风险降低相关,且未增加出血并发症风险。

研究设计与样本

  • 单中心回顾性研究,分析2009年7月至2014年4月期间治疗的动脉瘤性蛛网膜下腔出血患者。
  • 312例患者中161例符合纳入标准并纳入分析,分为DAPT组(85例,因支架辅助弹簧圈栓塞或血流导向装置置入需DAPT)和对照组(76例,仅弹簧圈栓塞未用DAPT)。

主要发现

  • DAPT组临床血管痉挛风险显著低于对照组(OR 0.244,95%CI 0.097-0.615,p=0.003)。
  • DAPT组迟发性脑缺血风险显著低于对照组(OR 0.056,95%CI 0.01-0.318,p=0.001)。
  • 两组外引流及脑室腹腔分流相关出血并发症发生率相似(4% vs 2%,p=0.9)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Clinical vasospasm and delayed cerebral ischemia (DCI) are devastating complications of aneurysmal subarachnoid hemorrhage (aSAH). Several theories involving platelet activation have been postulated as potential explanations of the development of clinical vasospasm and DCI. However, the effects of dual antiplatelet therapy (DAPT; aspirin and clopidogrel) on clinical vasospasm and DCI have not been previously investigated. The objective of this study was to evaluate the effects of DAPT on clinical vasospasm and DCI in aSAH patients. METHODS Analysis of patients treated for aSAH during the period from July 2009 to April 2014 was performed in a single-institution retrospective study. Patients were divided into 2 groups: patients who underwent stent-assisted coiling or placement of flow diverters requiring DAPT (DAPT group) and patients who underwent coiling only without DAPT (control group). The frequency of symptomatic clinical vasospasm and DCI and of hemorrhagic complications was compared between the 2 groups, utilizing univariate and multivariate logistic regression. RESULTS Of 312 aSAH patients considered for this study, 161 met the criteria for inclusion and were included in the analysis (85 patients in the DAPT group and 76 patients in the control group). The risks of clinical vasospasm (OR 0.244, CI 95% 0.097-0.615, p = 0.003) and DCI (OR 0.056, CI 95% 0.01-0.318, p = 0.001) were significantly lower in patients receiving DAPT. The rates of hemorrhagic complications associated with placement of external ventricular drains and ventriculoperitoneal shunts were similar in both groups (4% vs 2%, p = 0.9). CONCLUSIONS The use of DAPT was associated with a lower risk of clinical vasospasm and DCI in patients treated for aSAH, without an increased risk of hemorrhagic complications.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Nagahama Y, Allan L, Nakagawa D, et al. Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia. J Neurosurg. 2017. PMID: 29099296. doi:10.3171/2017.5.JNS17831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。